Previous 10 | Next 10 |
Iovance Biotherapeutics (NASDAQ: IOVA ) announces preliminary data from cohort 4 in its Phase 2 clinical trial evaluating lifileucel (LN-144) in metastatic melanoma patients. More news on: Iovance Biotherapeutics, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
SAN CARLOS, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (Nasdaq: IOVA) (“Iovance” or “Company”), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL and periph...
Cohort 4 Early Data Shows 32.4% ORR by Investigator Assessment at 5.3 Months of Median Study Follow up Cohort 2 Median Duration of Response Not Reached at 18.7 Months of Median Study Follow Up and 36.4% ORR SAN CARLOS, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeuti...
Median Duration of Response Not Reached at 17.0 Months of Median Study Follow Up in C-144-01 Study Oral Presentation to Include Additional Cohort 2 Data from C-144-01 Clinical Study at ASCO 2020 Virtual Scientific Program SAN CARLOS, Calif., May 13, 2020 (GLOBE NEWSWIRE) ...
Biotech Pulse Source: COVID-19 image by Getty Images; edits by PrudentBiotech.com It has taken a pandemic for biotechs to take flight towards their all-time high. One of the first industry groups to recover from the virus-related selloff and be neutral for the year, biotech indexes hav...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
Image source: The Motley Fool. Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) Q1 2020 Earnings Call May 05, 2020 , 4:30 p.m. ET Operator Continue reading
Iovance Biotherapeutics, Inc. (IOVA) Q1 2020 Earnings Conference Call May 05, 2020 4:30 PM ET Company Participants Sara Pellegrino - Vice President Investor & Public Relations Maria Fardis - President & Chief Executive Officer Friedrich Finckenstein - Chief Medical Office...
Iovance Biotherapeutics (NASDAQ: IOVA ): Q1 GAAP EPS of -$0.55 misses by $0.03 . Cash and equivalents of $312.5M. Shares +2.3% AH. Press Release More news on: Iovance Biotherapeutics, Inc., Earnings news and commentary, Healthcare stocks news,
SAN CARLOS, Calif., May 05, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL and peripheral-blood lymphocyte, PBL), today reported first quarter ...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
8.86%Change Percent:
Iovance Biotherapeutics Inc. Company Name:
IOVA Stock Symbol:
NASDAQ Market:
Iovance Biotherapeutics Inc. Website:
2024-07-29 18:24:26 ET No investor likes it when one of their stocks is hit with a recommendation downgrade from an analyst. That was the dynamic behind Iovance Biotherapeutics ' (NASDAQ: IOVA) more than 2% decline in value on Monday. A onetime Iovance bull has considerably cooled o...
SAN CARLOS, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its second quarter and...
2024-07-29 05:15:07 ET Piper Sandler analyst issues NEUTRAL recommendation for IOVA on July 29, 2024 02:11AM ET. The previous analyst recommendation was Overweight. IOVA was trading at $9.25 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...